Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPeptide Group AGPLYGF 61 Owner Earnings per Share (TTM) is 0.22 as of Dec. 2025, which is 99% below its 10-year median of 21.96. GuruFocus rates PLYGF with a GF Scoreâ„¢ of 61/100 and a GF Valueâ„¢ of $40.89 (Fairly Valued). The stock has 6 warning signs investors should review. Among 476 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 93.28% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
PolyPeptide Group AG's Owner Earnings per Share (TTM) ended in Dec. 2025 was $0.22. It's Price-to-Owner-Earnings ratio for today is 195.45.
The historical rank and industry rank for PolyPeptide Group AG's Owner Earnings per Share (TTM) or its related term are showing as below:
PLYGF'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.66 Med: 21.96 Max: 231.92
Current: 196.01
PLYGF's Price-to-Owner-Earnings is ranked worse than 93.28% of 476
companies
in the Drug Manufacturers industry
Industry Median: 24.33
vs PLYGF: 196.01
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
PolyPeptide Group AG Owner Earnings per Share (TTM) Related Terms
PolyPeptide Group AG Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG Owner Earnings per Share (TTM) Chart
PLYGF vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Price-to-Owner-Earnings vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income.
PolyPeptide Group AG's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was $1.3 Mil.
4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $51.9 Mil
It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.
The following shows how to get maintenance capital expenditure.
First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.
PolyPeptide Group AG's 5-Year Average Maintenance Capital Expenditure = $51.9 Mil
5. "Change In Working Capital" is from cashflow statement. PolyPeptide Group AG's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was $45.5 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Owner Earnings per Share (TTM) of 0.22 mean?
PolyPeptide Group AG (PLYGF) has a Owner Earnings per Share (TTM) of 0.22 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on PolyPeptide Group AG. This is 99% below median its historical median of 21.96. Over the past decade, PolyPeptide Group AG's Owner Earnings per Share (TTM) has ranged from 12.66 to 231.92. According to the industry distribution chart, PolyPeptide Group AG ranks #444 out of 476 companies in the Drug Manufacturers industry, placing it in the top 93.3%.
Is PolyPeptide Group AG's Owner Earnings per Share (TTM) too high?
PolyPeptide Group AG's current Owner Earnings per Share (TTM) of 0.22 is 99% below median its 10-year median of 21.96. Over the past 10 years, this metric has ranged from a low of 12.66 to a high of 231.92. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 24.33. PolyPeptide Group AG's value of 0.22 is 99.1% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #444 out of 476 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PolyPeptide Group AG has a GF Scoreâ„¢ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #444 out of 476 companies for Owner Earnings per Share (TTM). This places PolyPeptide Group AG in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.33. PolyPeptide Group AG's value of 0.22 is 99.1% below this benchmark. Historically, PolyPeptide Group AG's own Owner Earnings per Share (TTM) has ranged from 12.66 to 231.92 over the past decade. While the company's 10-year median is 21.96 vs. the industry median of 24.33, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 24.33, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Owner Earnings per Share (TTM) of 0.22 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on PolyPeptide Group AG. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 24.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Owner Earnings per Share (TTM) is 0.22, which is 99% below median its own 10-year median of 21.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Fairly Valued. The stock's GF Value™ is $40.89, compared to a current price of $43.00 — trading 5.2% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.22, which is 99% below median its 10-year median of 21.96 and 99.1% below the Drug Manufacturers industry median of 24.33. PolyPeptide Group AG's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Owner Earnings per Share (TTM) is 0.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of $43.00 is trading 5.2% above its estimated GF Value™ of $40.89.
GuruFocus considers PolyPeptide Group AG to be Fairly Valued.
Key valuation signals for PLYGF:
Owner Earnings per Share (TTM): 0.22 (99% below median its 10-year median of 21.96)
GF Value™: $40.89 vs. price of $43.00 (5.2% above fair value)
Industry Position: 99.1% below the Drug Manufacturers median (#444 of 476)
No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
61GF Score
Get the complete analysis for PLYGF
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLYGF has been successfully added to your 
